8-K

CVS HEALTH CORPORATION

Date: December 21, 2020

/s/ Eva C. Boratto

Eva C. Boratto

Executive Vice President and Chief Financial Officer

0001193125-20-323177.txt : 20201221 0001193125-20-323177.hdr.sgml : 20201221 20201221163448 ACCESSION NUMBER: 0001193125-20-323177 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20201221 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201221 DATE AS OF CHANGE: 20201221 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 201404713 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 8-K 1 d30843d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 21, 2020

LOGO

CVS HEALTH CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

001-01011

05-0494040

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)


One CVS Drive, Woonsocket, Rhode Island		02895
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (401) 765-1500

Former name or former address, if changed since last report: N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.01 per share

CVS

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Section 8 - Other Events

Item 8.01.

Other Events

On December 21, 2020, CVS Health Corporation, a Delaware corporation (the “Company”), issued press releases announcing the (A) early results and upsize of its previously announced cash tender offers (each, a “Tender Offer” and collectively, the “Tender Offers”) and (B) pricing of the Tender Offers. The Tender Offers were upsized by increasing the Aggregate Maximum Amount (as defined below) of the Tender Offers to $4,500,000,000 from $4,000,000,000 and by increasing the 2025 Notes Maximum Amount (as defined below) to $1,049,919,000 from $1,000,000,000 and the 2028 Notes Maximum Amount (as defined below) to $1,950,081,000 from $1,500,000,000.

The Tender Offers, as amended, consist of (i) up to $1,500,000,000 aggregate principal amount (the “2023 Notes Maximum Amount”) of its 4.000% Senior Notes due 2023 and 3.700% Senior Notes due 2023 and the 2.800% Senior Notes due 2023 issued by its wholly-owned subsidiary, Aetna Inc. (collectively, the “2023 Notes”), (ii) up to $1,049,919,000 aggregate principal amount (as increased and amended, the “2025 Notes Maximum Amount”) of its 4.100% Senior Notes due 2025 and 3.875% Senior Notes due 2025 (collectively, the “2025 Notes”) and (iii) up to $1,950,081,000 aggregate principal amount (as increased and amended, the “2028 Notes Maximum Amount”) of its 4.300% Senior Notes due 2028 (the “2028 Notes”, and, together with the 2023 Notes and the 2025 Notes, the “Notes”) validly tendered and accepted for purchase in connection with the Company’s previously announced cash tender offers commenced on December 7, 2020. The sum of the 2023 Notes Maximum Amount, the 2025 Notes Maximum Amount and the 2028 Notes Maximum Amount is $4,500,000,000 (as increased and amended, the “Aggregate Maximum Amount”).

Because the Company expects to accept for purchase the Maximum Aggregate Amount of Notes, no additional Notes are expected to be purchased pursuant to the Tender Offers after December 22, 2020, the early settlement date for such Notes validly tendered and accepted for purchase by the Company.

Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2, which are incorporated by reference herein.

Section 9 - Financial Statements and Exhibits

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

The exhibits to this Current Report on Form 8-K are as follows:

INDEX TO EXHIBITS


Exhibit		Description

99.1		Press Release of CVS Health Corporation dated December 21, 2020

99.2		Press Release of CVS Health Corporation dated December 21, 2020

104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-99.1 2 d30843dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO


Investor	Valerie Haertel	Media	T.J. Crawford
Contact:	Senior Vice President	Contact:	Vice President
	Investor Relations		External Affairs
	(401) 770-4050		(212) 457-0583

FOR IMMEDIATE RELEASE

CVS Health Corporation Announces Early Results and Upsize of Previously Announced Cash Tender Offers

to an Aggregate Principal Amount of $4,500,000,000 from $4,000,000,000 of Certain Outstanding Notes

WOONSOCKET, RI, December 21, 2020 – CVS Health Corporation (“CVS Health”, NYSE: CVS) announced today the early results of the previously announced cash tender offers (each, a “Tender Offer” and collectively, the “Tender Offers”) and that it is amending the Tender Offers by increasing the Aggregate Maximum Amount (as defined below) of the Tender Offers to $4,500,000,000 from $4,000,000,000 and by increasing the 2025 Notes Maximum Amount (as defined below) to $1,049,919,000 from $1,000,000,000 and the 2028 Notes Maximum Amount (as defined below) to $1,950,081,000 from $1,500,000,000. The Tender Offers, as amended, consist of (i) up to $1,500,000,000 aggregate principal amount (the “2023 Notes Maximum Amount”) of its 4.000% Senior Notes due 2023 and 3.700% Senior Notes due 2023 and the 2.800% Senior Notes due 2023 issued by its wholly-owned subsidiary, Aetna Inc. (collectively, the “2023 Notes”) in the priorities set forth in the table below (the “2023 Notes Tender Offers”), (ii) up to $1,049,919,000 aggregate principal amount (as increased and amended, the “2025 Notes Maximum Amount”) of its 4.100% Senior Notes due 2025 and 3.875% Senior Notes due 2025 (collectively, the “2025 Notes”) in the priorities set forth in the table below (the “2025 Notes Tender Offers”) and (iii) up to $1,950,081,000 principal amount (as increased and amended, the “2028 Notes Maximum Amount” and, together with the 2023 Notes Maximum Amount and the 2025 Notes Maximum Amount, the “Maximum Amounts”) of its 4.300% Senior Notes due 2028 (the “2028 Notes”, and, together with the 2023 Notes and the 2025 Notes, the “Notes”). Each group of Tender Offers that constitutes the 2023 Notes Tender Offers, the 2025 Notes Tender Offers or the 2028 Notes Tender Offer are referred to as the “Capped Tender Offers”. The sum of the increased 2023 Notes Maximum Amount, the 2025 Notes Maximum Amount and the 2028 Notes Maximum Amount is $4,500,000,000 (as increased and amended, the “Aggregate Maximum Amount”), which represents the aggregate principal amount of the Notes subject to the Tender Offers and excludes any Accrued Interest (as defined below) or Early Tender Payment (as defined below). The Tender Offers are being made upon the terms and subject to the conditions set forth in the Offer to Purchase dated December 7, 2020 (as amended or supplemented from time to time, the “Offer to Purchase”), which sets forth a detailed description of the Tender Offers. The Tender Offers are open to all registered holders (individually, a “Holder” and collectively, the “Holders”) of the Notes.


Capped Tender Offers	Title of Notes	CUSIP Number	Original Issuer	Acceptance Priority Level⁽¹⁾	Early Tender Payment⁽²⁾	Principal Amount Outstanding	Principal Amount Tendered	Principal Amount Expected to be Accepted for Purchase
2023 Notes Tender Offers	4.000% Senior Notes due 2023	126650 CC2	CVS Health	1	$30	$527,191,000	$113,284,000	$113,284,000
	3.700% Senior Notes due 2023	126650 CV0	CVS Health	2	$30	$3,722,809,000	$2,027,582,000	$1,386,716,000⁽³⁾
	2.800% Senior Notes due 2023	00817Y AV0	Aetna	3	$30	$1,300,000,000	$711,112,000	$0
2025 Notes Tender Offers	4.100% Senior Notes due 2025	126650 CW8	CVS Health	1	$30	$2,000,006,000	$1,049,919,000	$1,049,919,000
2025 Notes Tender Offers	3.875% Senior Notes due 2025	126650 CL2	CVS Health	2	$30	$2,828,067,000	$924,598,000	$0
2028 Notes Tender Offer	4.300% Senior Notes due 2028	126650 CX6	CVS Health	1	$30	$9,000,000,000	$4,491,692,000	$1,950,081,000⁽³⁾

(1)

Subject to the Aggregate Maximum Amount, the Maximum Amounts and proration, the principal amount of each series of Notes that is purchased in each of the Tender Offers will be determined in accordance with the applicable acceptance priority level (in numerical priority order) specified in this column.

(2)	Per $1,000 principal amount of Notes validly tendered at or prior to the Early Tender Date and accepted for purchase.

(3)	After application of proration.

The consideration to be paid in the Tender Offers for each series of Notes validly tendered and expected to be accepted for purchase as described in the Offer to Purchase (the “Total Consideration”) will be determined at 9:00 a.m., New York City time, on December 21, 2020.

As of 5:00 p.m., New York City time, on December 18, 2020 (the “Early Tender Date”), as reported by D.F. King & Co., Inc., the Tender and Information Agent for the Tender Offers, the principal amounts of the Notes listed in the table above have been validly tendered and not validly withdrawn. The Withdrawal Deadline of 5:00 p.m., New York City time, on December 18, 2020 has passed and, accordingly, Notes validly tendered in the Tender Offers may no longer be withdrawn.

CVS Health expects to accept for purchase and make payment for Notes validly tendered and not validly withdrawn at or prior to the Early Tender Date on December 22, 2020 (the “Early Settlement Date”), subject to the acceptance priority levels applicable to the relevant series as described in the Offer to Purchase and, in the case of the 3.700% Senior Notes due 2023 for the 2023 Notes Tender Offers and in the case of the 4.300% Senior Notes due 2028 for the 2028 Notes Tender Offer to proration as described below.

Because the aggregate principal amount of 2023 Notes validly tendered would exceed the 2023 Notes Maximum Amount, CVS Health expects that it will accept validly tendered 3.700% Senior Notes due 2023 on a prorated basis in accordance with the Offer to Purchase and none of the validly tendered 2.800% Senior Notes due 2023. Because the aggregate principal amount of 2025 Notes validly tendered would exceed the 2025 Notes Maximum Amount, CVS Health expects that it will accept all of the validly tendered 4.100% Senior Notes due 2025 and none of the 3.875% Senior Notes due 2025. Because the principal amount of 2028 Notes validly tendered would exceed the 2028 Notes Maximum Amount, CVS Health expects that it will accept validly tendered 4.300% Senior Notes due 2028 on a prorated basis in accordance with the Offer to Purchase.

Because CVS Health expects to accept for purchase the Maximum Aggregate Amount of Notes, no additional Notes will be purchased pursuant to the Tender Offers after the Early Settlement Date. In connection with the recent announcement by the U.S. government that executive departments and agencies of the federal government will be closed on December 24, 2020, the expiration date (the “Expiration Date”) will be changed from 11:59 p.m., New York City time, January 5, 2021 to 11:59 p.m., New York City time, January 6, 2021. As described in the Offer to Purchase, Notes tendered and not accepted for purchase will be promptly returned to the tendering Holder’s account.

Holders of all Notes validly tendered and not validly withdrawn at or prior to the Early Tender Date and accepted for purchase are eligible to receive the applicable Total Consideration, which includes the applicable Early Tender Payment of $30 per $1,000 principal amount of Notes tendered at or prior to the Early Tender Date (the “Early Tender Payment”). In addition to the applicable Total Consideration, Holders of Notes accepted for purchase will receive accrued and unpaid interest up to, but not including, the Early Settlement Date (“Accrued Interest”).

CVS Health expressly reserves the right, in its sole discretion, subject to applicable law, to terminate the Tender Offers at any time prior to the Expiration Date. The Tender Offers are not conditioned on any minimum principal amount of Notes being tendered but the Tender Offers are subject to certain conditions as described in the Offer to Purchase. Each Tender Offer is a separate offer. None of the Capped Tender Offers are conditioned on each other. Each Tender Offer may be individually amended, extended or terminated by CVS Health.

CVS Health has retained Barclays Capital Inc., BofA Securities, Inc. and Goldman Sachs & Co. LLC to act as Dealer Managers for the Tender Offers. D.F. King & Co., Inc. has been retained to act as the Tender and Information Agent for the Tender Offers. Requests for assistance relating to the procedures for tendering Notes may be directed to the Tender and Information Agent either by email at cvs@dfking.com, or by phone (212) 269-5550 (for banks and brokers only) or (800) 714-3305 (for all others toll free). Requests for assistance relating to the terms and conditions of the Tender Offers may be directed to Barclays Capital Inc. at (800) 438-3242 (toll free) or (212) 528-7581 (collect), BofA Securities, Inc. at (980) 387-3907 (collect) or Goldman Sachs & Co. LLC at (212) 902-6351 (collect). Beneficial owners may also contact their broker, dealer, commercial bank, trust company or other nominee for assistance.

This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders with respect to, the Notes. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Tender Offers are being made solely pursuant to the Offer to Purchase made available to Holders of the Notes. None of CVS Health, the Dealer Managers, Tender and Information Agent or the trustees with respect to the Notes, or any of their respective affiliates, is making any recommendation as to whether or not Holders should tender or refrain from tendering all or any portion of their Notes in response to the Tender Offers. Holders are urged to evaluate carefully all information in the Offer to Purchase, consult their own investment and tax advisers and make their own decisions whether to tender Notes in the Tender Offers, and, if so, the principal amount of Notes to tender.

About CVS Health

CVS Health is a different kind of health care company. We are a diversified health services company with nearly 300,000 employees united around a common purpose of helping people on their path to better health. In an increasingly connected and digital world, we are meeting people wherever they are and changing health care to meet their needs. Built on a foundation of unmatched community presence, our diversified model engages one in three Americans each year. From our innovative new services at HealthHUB^® locations, to transformative programs that help manage chronic conditions, we are making health care more accessible, more affordable… and simply better. Learn more about how we’re transforming health at www.cvshealth.com.

Cautionary Statement Concerning Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties related to the COVID-19 pandemic, the geographies impacted and the severity and duration of the pandemic, the pandemic’s impact on the U.S. and global economies and consumer behavior and health care utilization patterns, and the timing, scope and impact of stimulus legislation and other federal, state and local governmental responses to the pandemic, as well as the risks and uncertainties described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 and our recently filed Current Reports on Form 8-K.

You are cautioned not to place undue reliance on CVS Health’s forward looking statements. CVS Health’s forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

EX-99.2 3 d30843dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

LOGO


Investor	Valerie Haertel	Media	T.J. Crawford
Contact:	Senior Vice President	Contact:	Vice President
	Investor Relations		External Affairs
	(401) 770-4050		(212) 457-0583

FOR IMMEDIATE RELEASE

CVS Health Corporation Announces Pricing of Tender Offers

WOONSOCKET, RI, December 21, 2020 – CVS Health Corporation (“CVS Health”, NYSE: CVS) announced today the applicable Reference Yields and Total Consideration (each as summarized in the table below) to be paid in connection with the previously announced cash tender offers (each, a “Tender Offer” and collectively, the “Tender Offers”) for (i) up to $1,500,000,000 aggregate principal amount (the “2023 Notes Maximum Amount”) of its 4.000% Senior Notes due 2023 and 3.700% Senior Notes due 2023 and the 2.800% Senior Notes due 2023 issued by its wholly-owned subsidiary, Aetna Inc. (collectively, the “2023 Notes”) in the priorities set forth in the Offer to Purchase (as defined below) (the “2023 Notes Tender Offers”), (ii) up to $1,049,919,000 aggregate principal amount (the “2025 Notes Maximum Amount”) of its 4.100% Senior Notes due 2025 and 3.875% Senior Notes due 2025 (collectively, the “2025 Notes”) in the priorities set forth in the Offer to Purchase (the “2025 Notes Tender Offers”) and (iii) up to $1,950,081,000 principal amount (the “2028 Notes Maximum Amount” and, together with the 2023 Notes Maximum Amount and the 2025 Notes Maximum Amount, the “Maximum Amounts”) of its 4.300% Senior Notes due 2028 (the “2028 Notes”, and, together with the 2023 Notes and the 2025 Notes, the “Notes”). Each group of Tender Offers that constitutes the 2023 Notes Tender Offers, the 2025 Notes Tender Offers or the 2028 Notes Tender Offer are referred to as the “Capped Tender Offers”. The sum of the 2023 Notes Maximum Amount, the 2025 Notes Maximum Amount and the 2028 Notes Maximum Amount is $4,500,000,000 (the “Aggregate Maximum Amount”), which represents the aggregate principal amount of the Notes subject to the Tender Offers and excludes any Accrued Interest (as defined below) or Early Tender Payment (as defined below). The Tender Offers are being made upon the terms and subject to the conditions set forth in the Offer to Purchase dated December 7, 2020 (as amended or supplemented from time to time, the “Offer to Purchase”), which sets forth a detailed description of the Tender Offers. The Tender Offers are open to all registered holders (individually, a “Holder” and collectively, the “Holders”) of the Notes.

The applicable Reference Yield for the Notes and the Total Consideration for the Notes are summarized in the table below:

Capped

Tender Offers

Title of Notes

CUSIP
Number

Original
Issuer

Acceptance
Priority Level

UST Reference
Security

Fixed
Spread
(bps)

Reference
Yield

Total
Consideration⁽³⁾

2023 Notes

Tender Offers⁽¹⁾

4.000% Senior Notes due 2023

126650 CC2

CVS Health

0.250% UST due 11/15/2023

0.158%

$1,097.88

3.700% Senior Notes due 2023

126650 CV0

CVS Health

0.250% UST due 11/15/2023

0.158%

$1,070.87

2025 Notes

Tender Offers⁽²⁾

4.100% Senior Notes due 2025

126650 CW8

CVS Health

0.375% UST due 11/30/2025

0.356%

$1,137.08

2028 Notes

Tender Offer

4.300% Senior Notes due 2028

126650 CX6

CVS Health

0.875% UST due 11/15/2030

0.906%

$1,187.37

(1)	Because the aggregate principal amount of 2023 Notes validly tendered would exceed the 2023 Notes Maximum Amount, none of the validly tendered 2.800% Senior Notes due 2023 are expected to be accepted for purchase.

(2)	Because the aggregate principal amount of 2025 Notes validly tendered would exceed the 2025 Notes Maximum Amount, none of the validly tendered 3.875% Senior Notes due 2025 are expected to be accepted for purchase.

(3)	Per $1,000 principal amount of Notes validly tendered at or prior to the Early Tender Date and accepted for purchase.

The Total Consideration for each $1,000 principal amount of the Notes was determined in the manner described in the Offer to Purchase by reference to the applicable fixed spread set forth in the table above plus the yield to maturity or first par call date, as the case may be, of the applicable U.S. Treasury reference securities (the “UST Reference Security”) set forth in the table above on the bid-side price of such UST Reference Security as of 9:00 a.m., New York City time, on December 21, 2020.

The Notes validly tendered and not validly withdrawn at or prior to 5:00 p.m., New York City time, on December 18, 2020 (the “Early Tender Date”) will be eligible to receive the applicable Total Consideration, which includes the Early Tender Payment of $30 per $1,000 principal amount of Notes.

About CVS Health

Cautionary Statement Concerning Forward-Looking Statements

EX-101.SCH 4 cvs-20201221.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 cvs-20201221_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 cvs-20201221_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g30843g1219085544304.jpg GRAPHIC begin 644 g30843g1219085544304.jpg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g30843g1221082151365.jpg GRAPHIC begin 644 g30843g1221082151365.jpg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end GRAPHIC 9 g30843g1221211848993.jpg GRAPHIC begin 644 g30843g1221211848993.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#:^)GQ&9Y) M=!T2Z*?3U/X5QW@KQQ>^$]3!+R3:=*<3VY;/_ E]&'ZU0\5^ M&;WPMK4MG=J61B6@F[2IGK]?4>M85>14JU/:*+LVE@\D.DQGY5R5,Q_O-[>@J_\ #GXBR:).FE:Q,SZ;(<1R MN@SZ=_H*^=M5\2^(/%-]BYN[ MB=I6PEM#G8/94'_ZZ[SXPJ^GZ1X;T@2%T@B;+'^(JJJ#_/\ .H/@C913:[J- MXZAI+>!5C)'W=Q.2/P&/QKIK.52JJ=[(\7+J='!X&6-<>:73[[+T."_XGWAF MZ0G[?IDY^9<[HB?\:ZO4_&6J^(_!\=S]MN(-2TR4+.UO(T8FB?@.0I R& !^ MOO7LOBKPI8^+=-CLKUY(Q'()$DBQN4X(QR#PI%M1>@EG&$KQC4K1M43[?KZ'*_"/Q'?3>*Y;"^OKFX2 MYMVV":9GPR\\9/IFMWXRZ_=:?;:9865U-;RRNTSM#(4.T# &1VR3^5>5>%K] MM%\7:;=OE/)N560>@)VM^A-;?Q5U/^T?'=TBMF.T1;=?J!EOU)_*LU5:H-=; MG94P$99K"HE[O+?[M/U0[0/%>L:+HVH:R]]=7$SD6=H)YF=$<_,S[2<$A0,? M[U8D$'B/QE?R+$;S4[A1O?=)G:/Q.!7=:AX&O)/A%I3V<+27D3F]FB4?,RN. MP[D#;Q[&O/=%U_5?#=\USIERUO,1L<%00P]"#433C:,[V.G"RIU54JX91Y[M M:^6BVZ/L^(_!VJM%'<7-G<0-B2VE)V'OAE/!!_\ U5[A<(OQ&\ VL\&I M7NE&;$K264FUU9XBB'F8^C9S^8KV+ M3+G3;W0$NM)$0LI8RT?E(%'OP.ASUKJPMKOEE==CP<]67\R>C_KS/ M)/@5IVH:M#-XCOO$6K7+VUQ):BTFN&>)AM7YB">OS5ZEXLT!O$FAM8IJE[II M#B3S[*39)QGC/H:\/^$GC#6?#_AJ]M=.\':EK,3WSR&XMFPJG:HV_=// /XU MWK_$WQ08V!^&.N#(/.__ .PKL/FS ^!.GZAJ]O+XDO\ Q#JUR]O<26PM)KAG MB8;5^8@D\\U[?7CGP N8K/X<:K=7#>7##?2R2,?X5$:$G\JAT>'Q7\7FN=8D MUV\T#PV)6CL[:R.V68*<%F8'_$9R .* /::*\3UNV\5_"!K?6[?7[W7O#OFK M'>6M\VZ2,,<95B?U&.<9!S73_$;Q_BT5Y+;_"?Q,UN+ZZ^(FLKK1&XM&[&!6]-I/(_+Z5R-C?\ CSQ) M\4SX5U3Q'=Z/_2N+\9_P#)P/@?_KW?_P!J5S?Q3\-:I'\0_#3-XGO7&IZBWV4%?^/#+I_J M^><9'IT% 'H/Q?TJXNO!MQJUMK&HZ?-I<,DRK9S&,3$XX?'4#'ZFM;X9W,]W M\-M!N+F:2>:2U!>25RS,1_M5P,-@XP MO4\"N.\ ^#/$GC'P1IMQJ'BB_P!)TN*+RK*TTX^66521O0^'-3\0^!?B-;>#->U:75],U*(OI]W/S(C#/RDDD]B,9/4$8R17KU &-XE\ M-V'BG2'L+Y/]J*51\T3]F'^'>OFSQ%X>OO#.KR:??IAEY20?=E7LR_YXKZLK MGO&'A>Q\4Z+);W8V2Q O!.HRT;8_4'N*YL105176Y[649K+!SY)ZP?X>:/FO M2]*O-:U*'3["$RW$QPJCH/4D]@/6OI#P9X.L_".E""+$MY* ;BXQRY]!Z*.P MJC\.O"=CX?T&&[B_>WEY&LDL[+@X/(4>@'ZUV=+#4%!?\ PX\6V_A/7I9+T/\ 8[F/RY60 M9*$'(;'?O^=?1=Q;PW=O);W$2RPRJ4='&0P/4&O#?'GPVLO#\;7]A>R"!R2+ M>1-VWV#9Z?45&(IRC/VL#IRG&T*N'> Q'7;\_P S;\=_%.TDTV.U\,7TOVEY M TEPB%0BCM\PY)XJ/X5:YXDU_P 07#W^IW%Q8VT!W*^-I=C\O;KP37!^#O"8 M\5:@+9KTVRYY(BW'^8KZ%\/>'-/\,:4MAIT95 =SNQRTC>K&E1]I5GSO8K,O MJ>!P[PM.-YOJUJOG_D?/_P 1=(_L7QQ?QHNV*=OM,6/1^3_X]FLO1K*?Q)XI MM+65VDEO+@>:YZX)RQ_+->U_$;P5'XFFL;H7GV6:)6C)\K?O7@CN.G/YU0\ M_#Z/0?$+:C)?_:GCA98U\C9M+<9SN/;(_&HEAY.KY'71SFC' )M_O%&VSWVW M-SQWXNNO!5G82VNG17-O*QB)9RNP@#:.!W&?RKB;'QKX3\77DT?BO1;*S8KF M.Y7<2Q[@LH!%>LZUHMCK^E3:=J$7F02CG!P5/8@]B*^>_&O@M/"=YY<=\US& MW*[HMI ]SGG\A6N(=2+YEK$\_)XX2O#V4KQJ]&F[_P"1F^+(-!MM>DC\.7,D M]AL!W/GANX!(!(Z5Z_\ "%9E\ 3F3/EM<2F+/I@9_7->?^!O $'BF3S+F_>& M%.6CCC&YAZ!B>/R->M>)M'NK7P?#IGAS4FT4PNBI+'$)"$YR,$CKZU.%IRYO M:/1&^>8RFJ*P<6Y25KM^7ZG'_L\_\B/J/_83D_\ 0$KUJ;_4R?[IKR;X8^#= M5\):L(%\2O,6D:N^E71E7_2$B M$AV\Y7!(ZUW'RAY-\+[6>^^!7BVUM@3/*]RJ =2?*7BD^&7A+6_$/@2RN],^ M(.I:?"C/$UG#$"L+!CD?>'7(;_@5=!\,?!FJ^$=66W7Q*]SIC^9))9?9 BLY M &[=N)[#\JJ^,/"=Y\/[FZ\2>#]=FTN.[DW3Z?Y*RPLWJ 3@?3!QV('% %C7 MOAEJXNO/TVWM5LT MNF&%9A\H;T'WU/6K'A3PQJ'Q+>WUGQCK\VHV=I(&CTU(%BA+>K;3R/PS[XKT MOQAX-TOQIH#:3J*%5!WPRQ@!H7 P&7^6.XH Z&O&;:^MKW]J&86S*WV?3C#* M5_OAY\<6>OKX+A\;S_9PWDK=-9HTJKTX).[_QZM*;X43^&_%$ M-_X=\37%C<+ $EEDMQ,\K-]]B2V/F],<4 :OC3_DX+P1_P!>\G_M2E^+/_)0 M/AW_ -A$_P#H<=:_Q/\ !\FK-IWB2PU633=5TDGRIDB#[@3TP2.A^O4\57\4 M^#;GQ5X&T2^N=;ECUK2E%S'J"0C+MP3\H(QR%/!XQ0!T'Q0_Y)AXB_Z\V_I3 M?A7_ ,DN\/?]>@_F:X[4='\3^)/ -G977B^0-<23)=R?84_?QG;M4@$8Q@\C MKFND^&&AZGX>TR?3[W7&U*UA6-+6,VXB$"C=D#!).O5XIXL\%:]K/C/\ M?\ X2^2&2RN':Q3["K?9@3G .X9[=14O]D^ 1/O\ HH]Q_P""R/\ ^*H _]D! end XML 10 d30843d8k_htm.xml IDEA: XBRL DOCUMENT 0000064803 2020-12-21 2020-12-21 CVS HEALTH Corp false 0000064803 8-K 2020-12-21 DE 001-01011 05-0494040 One CVS Drive Woonsocket RI 02895 (401) 765-1500 false false false false Common Stock, par value $0.01 per share CVS NYSE false XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Dec. 21, 2020
Cover [Abstract]
Entity Registrant Name	CVS HEALTH Corp
Amendment Flag	false
Entity Central Index Key	0000064803
Document Type	8-K
Document Period End Date	Dec. 21, 2020
Entity Incorporation State Country Code	DE
Entity File Number	001-01011
Entity Tax Identification Number	05-0494040
Entity Address, Address Line One	One CVS Drive
Entity Address, City or Town	Woonsocket
Entity Address, State or Province	RI
Entity Address, Postal Zip Code	02895
City Area Code	(401)
Local Phone Number	765-1500
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, par value $0.01 per share
Trading Symbol	CVS
Security Exchange Name	NYSE
Entity Emerging Growth Company	false

EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

$E5$<.&7J/P$ #P" / " 5(/ M !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " !7A)51)!Z;HJT #X 0 M&@ @ &^$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " !7A)5199!YDAD! #/ P $P @ &C$0 I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #M$@ ! end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d30843d8k.htm cvs-20201221.xsd cvs-20201221_lab.xml cvs-20201221_pre.xml d30843dex991.htm d30843dex992.htm g30843g1219085544304.jpg http://xbrl.sec.gov/dei/2019-01-31 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d30843d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d30843d8k.htm" ] }, "labelLink": { "local": [ "cvs-20201221_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cvs-20201221_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cvs-20201221.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cvs", "nsuri": "http://CVS/20201221", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d30843d8k.htm", "contextRef": "duration_2020-12-21_to_2020-12-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d30843d8k.htm", "contextRef": "duration_2020-12-21_to_2020-12-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://CVS//20201221/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 19 0001193125-20-323177-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-323177-xbrl.zip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end